ALT-702 / Altimmune - LARVOL DELTA

"#Altimmune Announces Positive Results for ALT-702 in #Preclinical Model of #ColorectalCancer https://t.co/zdIC9ZJZEn @biospace" (@PlexusVentures)

Preclinical

Altimmune announces positive results for ALT-702 in preclinical model of colorectal cancer (GlobeNewswire) - "Altimmune, Inc...announced that the Company’s immuno-oncology product candidate, ALT-702, met a key pre-clinical efficacy milestone with the demonstration of systemic antitumor activity following intra-tumoral injection in an individual solid tumor...The aggressive tumor model is based on the murine CT26 colorectal carcinoma cell line...the United States Patent and Trademark Office (USPTO) granted US Patent No. 10,434,183 (the ‘183 patent) entitled 'Immunogenic Compound.'....The issued patent will expire no earlier than 2034."

Patent • Preclinical

Newly added product (GlobeNewswire) - Preclinical, Oncology, CRC

Pipeline update